Rocket Pharmaceuticals gets FDA clearance for its gene therapy for Infantile Malignant Osteopetrosis

Rocket Pharmaceuticals has received clearance from the U.S. Food and Drug Administration (FDA) for the Company’s Investigational New Drug (IND) application for RP-L401, its, lentiviral vector (LVV)-based gene therapy for the treatment of Infantile Malignant Osteopetrosis (IMO), a rare, severe monogenic bone resorption disorder.

Read more

Piramal Pharma buys solid oral dosage drug product facility in Sellersville, Pennsylvania from G&W Laboratories Inc.

Piramal Enterprises Limited’s (PEL) Pharma Solutions business, a leading Contract Development and Manufacturing Organization (CDMO), has entered into an agreement with G&W Laboratories Inc. to acquire its solid oral dosage drug product manufacturing facility located in Sellersville, Pennsylvania. The transaction closure is subject to customary preclosing conditions.

Read more